Company intelligence / Profile preview

Oxy5 OncoMedical

Darmstadt, Hesse, Germany

Ownership: Private
Development stage: Other

Overview

Oxy5 OncoMedical AG is a German biopharmaceutical company focused on developing innovative cancer treatments by targeting tumor metabolism. The company's research centers on the inhibition of transketolase-like 1 (TKTL1), an enzyme crucial for the metabolic reprogramming of cancer cells, also known as the Warburg effect. Their lead candidate, benfo-oxythiamine (B-OT), is a small molecule prodrug that releases oxythiamine to inhibit transketolase activity, thereby sensitizing cancer cells to chemotherapy, radiotherapy, and immunotherapy. Oxy5 aims to address treatment resistance and improve outcomes for patients with therapy-resistant tumors.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

benfovir AG

Beyond the preview

Go deeper on Oxy5 OncoMedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxy5 OncoMedical.

Explore the full profile